Brief: Cantargia Says Preclinical Data Supports Nadunolimab In PDAC
30/09/2026 06:08
BRIEF-Cantargia Says Preclinical Data Supports Nadunolimab In PDAC Sept 30 (Reuters) - Cantargia AB CANTA.ST:
CANTARGIA HIGHLIGHTS PRECLINICAL DATA AT AACR SUPPORTING NADUNOLIMAB IN COMBINATION WITH RAS INHIBITION IN PDAC
TWO APPROACHES ACT ON NON-OVERLAPPING PARTS OF PDAC BIOLOGY, THAT COMBINATION RESHAPES TUMOR MICROENVIRONMENT, AND REDUCES TUMOR BURDEN
Source text: ID:nMFN8zdv7n
Further company coverage: CANTA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))